House bill would require in-person visits and state licensure for mifepristone prescriptions
/ 1 min read
Table of Contents
This bill, introduced in the House, would change how certain providers prescribe mifepristone, a medication used for medical abortions. Currently, under the FDA’s REMS (Risk Evaluation and Mitigation Strategy) program, some patients can receive this medication via telehealth or mail.
Why it matters: This would effectively end remote or mail-order access to mifepristone for patients whose doctors are located in different states or who only use telehealth services.
Who it affects
- Patients seeking medical abortions via telehealth or mail-order pharmacy
This information comes from Congress.gov; please consult the official text of the bill before relying on it for legal or medical decisions.
Agency: House
Source: Congress.gov — read the official document